RESI@TMCx Biotech Family Office Panel

By Michael Quigley, Director of Research, LSN

mike-2Earlier this month Life Science Nation’s RESI Conference at the TMCx in Houston was home to a panel of representatives and experts in the Family office world who spoke to how their groups go about sourcing and making investments in the therapeutic space. Key topics discussed include the position of family offices in the investment ecosystem, the differences and similarities between family offices and other investors, how family offices go about identifying opportunities, and what these particular groups are looking for right now.

Click on the video below to hear the views of these family offices speaker for yourself.

LSN Summer Reading Series Chapter 5: “Knowing Who and What You Are, and Where You Fit”

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10In this latest edition of the summer reading series, we will be explaining the importance of understanding where your opportunity fits within the marketplace. Knowing who you are and how you compare with other companies in the space is crucial in determining the investors to whom you should be reaching out, what you should be highlighting in your marketing materials, and, in some cases, whether you need to “pivot,” or change, your commercialization plan.

Chapter 5 of The Life Science Executive’s Fundraising Manifesto, “Knowing Who and What You Are, and Where You Fit,” discusses how to define yourself and your market, as well as the importance of being able to pivot after receiving feedback and how to identify when it is strategically relevant to do so.

Click here to download/print the PDF.

We hope this text proves to be informative. Join us next week for Chapter 6: “Branding and Messaging”, for some tactical tips on how to build a brand for your company.

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front

RESI Wraps Up in Houston and Heads Back to Boston

By Scott Parks, Director of Marketing, LSN 

Scott 2June 8th was the 5th Redefining Early Stage Investments (RESI) conference, and the first at Houston’s Texas Medical Center’s Innovation Portal (TMCx).  With nearly 500 registrations the 100,000 square-foot accelerator space was filled with CEOs, scientists, entrepreneurs and more than 150 investors (from LSN’s 10 investor categories including:  Family Offices, Hedge Funds, Venture and Private Equity). The venue served as an exhibition space as well as a partnering forum for investors and entrepreneurs who compressed a total of 700 meetings into a single day in order to network, build relationships and close investment rounds.

LSN’s CEO Dennis Ford comments, “It can be overwhelming and we absolutely love that aspect.  We want to give everyone who comes here more opportunities than they can make a decision about, because if we’re doing that, we’re doing our job. We really want to inundate everyone, for one day, and submerge them in this early stage investor world to let them get a lot of bang for their buck instead of stretching it out over a period of several days. We want to give them as much value as possible.”

Throughout the day, and in several conference rooms, panels and workshops provided platforms for investors to communicate directly to fundraising entrepreneurs. Topics covered included biotech angels and venture philanthropy.  The event offered firsthand accounts from investors explaining their current investment mandates and procedures for identifying and qualifying candidates.

RESI@TMCx provided the platform for early stage investors and life science entrepreneurs to make a compelling connection, and is a result of partnerships between Life Science Nation, Texas Medical Center, Johnson & Johnson Innovation, and JLABS (JLABS @TMC).

Those who missed the Houston event will have only 90 days to wait until RESI comes to Boston on September 16 at the Westin, Copley.  For now, the RESI conferences are limited to 3/year (Boston-Fall, San Francisco-Winter, Houston-Spring/Summer).  As interest and attendance continue to grow, so too will RESI’s frequency and geographic footprint.

RESI BOSTON Now Open for Registration

Registration (with early bird pricing) is now available for RESI Boston (September) and RESI SF (January).

RESI@Boston-Banner-600

sf16

Early-Bird-RESI-Boston-wp

Refining the Global Target List: How to Prioritize Investor Leads

By Lucy Parkinson, Senior Research Manager, LSN 

lucy 10*10While creating a target list of investor contacts is a good first step on your road to financing, lists have to be used strategically. It’s important to refine and prioritize your investor targets before embarking on a fundraising campaign, and in this article, I’ll explain how we conduct this process at LSN.

LSN’s primary goal is to help life science companies connect with investors who are a suitable fit for their opportunities. By searching the LSN Investor Platform, a fundraising executive can create a Global Target List (GTL) of potential investors in their company. This list typically includes 250 to 500 possible investors—enough to create a considerable amount of outreach work. So how can the list be filtered so this work can be conducted most effectively?

Our strategy is to divide this list into tiers, ranked by the quality of fit between your opportunity and the firm’s investment thesis. By using this method, you can focus on the most relevant life science investors first. Connecting to these highly promising targets may lead to securing a lead investor to anchor your raise, which will make it easier to fill out the rest of your financing round.

After generating a GTL, our next step is to go through the list and read each investor’s mandate one by one. This takes time, but it’s crucial if you want to focus your outreach effectively. You may find that several investors have specific criteria that your company doesn’t match; for example, you might discover that an investor is only interested in companies based within a very small geographic area, or associated with a particular university. It’s important to identify these “deal-breaker” criteria before wasting effort on initiating contact. We mark such investors as “Not a Fit” for the opportunity.

But among the investors who are relevant to your company, not all fits are alike. As we read through each investor’s criteria and areas of focus, we can divide these investors into three tiers: Strong Fit, Opportunistic Fit, and Tenuous Fit. We then tag each profile with a tier in our CRM system to allow for more efficient outreach.

So how do we define these three tiers?

A Strong Fit is an investor that has a specific interest that applies to your company in some regard. Perhaps the investor is highly focused on a certain medical indication or technology that you are addressing. For example, if an investor has expressed a particular interest in therapeutic platform technologies in the neurology space, and that’s exactly what your company is developing, you’re going to want to prioritize this investor! As you study each entity on your list, keep an eye open for a specific area of alignment, whether it’s a particular patient population or a field of technology that is of interest to the investor, or perhaps an underlying investment theme your company fits within, such as delivering care more cost efficiently. This is how you can identify the strongest fits that require the most urgent outreach and the most frequent follow-up.

The second tier consists of Opportunistic Fits. For these investors, you’re definitely in the ballpark of what they are interested in, but they’re not specifically focused on what you have to offer. Some life science investors are open to a wide range of approaches within certain parameters; for instance, they might have a general interest in preclinical therapeutic opportunities throughout North America, but they haven’t displayed a specific focus on technologies like yours. As these investors have a potential interest in what you do, they should be the targets of the second wave of outreach; you might not follow up with them as frequently as you would with the first tier, but there’s a strong potential for dialogue.

In the case of a Tenuous Fit, while there is a potential basis for a match between your company and the investor, you likely do not represent a typical deal for them. For example, if an investor focuses on companies based in the Northeast U.S., and your company is based in Toronto but is a good fit in other regards, it may be worth asking if they’d like to talk to you about the opportunity. Or perhaps the investor is interested in your area of medicine but usually only considers companies at the IND filing stage, whereas your lead asset is already in Phase II trials. Even though this company does not represent the perfect fit, they might prove to be a very important contact. In LSN’s experience, outreach to these “tenuous fits” has frequently resulted in good strategic connections and sometimes future investment opportunities. For example, the investor may be able to act as a “pointer,” that is, they may be able to refer you to another investor who is really interested in your field, or to other important strategic connections for your company. It’s therefore important to approach these “tenuous fits” as people with whom you want to have a conversation about your company, not necessarily as sources of capital; a broader discussion might reveal areas where you can work together, or might lay the groundwork for an investment in a future financing round.

Once you’ve categorized each investor into one of the above tiers, you’ll have a detailed picture of the investor landscape for your company. It’s a vital second step to take after generating your global target list. By executing this process, you’ll know where to make your first forays into fundraising, what to expect from each investor conversation, and how to focus your follow-up efforts, and will increase your odds of carrying out an efficient fundraising campaign.

LSN Summer Reading Series Issue #4

By Michael Quigley, Director of Research, LSN

 

mike-2This week in the summer reading series, we explore the current categories of early stage life science investors. As a result of the significant changes the investor landscape has undergone in the past few years, many traditional players have moved downstream to later stage investments or out of the space entirely, and new faces have stepped in to fill the void. Understanding what motivates these different groups and how they operate is crucial when looking for a successful financial partnership.

Chapter 4 of The Life Science Executive’s Fundraising Manifesto “Categories of Life Science Investors” explains how and why the funding landscape has changed, the types of investors who are currently funding companies, and, in general, the approach these entities take toward investing.

Click here to download/print the PDF.

We hope this text proves to be informative. Next week we will turn the focus inward with Chapter 5: “Knowing Who and What You Are, and Where You Fit.”

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front

Winners Announced From Latest RESI Innovation Challenge

By Nono Hu, Senior Manager, Branding & Messaging, LSN

Nono 2

This Monday, RESI came to TMCx, the Texas Medical Center’s 100,000-square-foot accelerator space. RESI @ TMCx featured approximately 150 investors, 250 biotech, medtech and healthcare IT entrepreneurs, and 60 service providers.

In the exhibit hall, 34 of the most innovative early stage life science companies at the event were chosen to participate in a virtual investment contest – The RESI Innovation Challenge, showcasing cutting-edge life science technologies in poster displays and competing to raise the most RESI Cash. Without further ado here are the top 3 contestants!

First Prize Winner: Redox

Redox is the modern API for healthcare integration. Redox helps developers integrate with EHRs and health systems manage their connections to the cloud. The Redox Engine de-risks software implementations by enabling turnkey EHR integration with any application you choose to work with.

As a first prize winner, Redox will receive complimentary subscription to the LSN Investor Platform.

Alejandro Zamorano, Director of Business Development, LSN | Niko Skievaski, Co-founder, Redox | James Lloyd, Co-founder & CTO, Redox | Michael Quigley, Director of Research, LSN

Second Prize Winner: NeuroFx

neu

NeuroFx has developed an innovative, cell-free therapeutic factor concentrate derived from adult adipose (fat) stem cells that has demonstrated great potential based on animal testing to not only reduce brain injury caused by stroke, but in addition promote regeneration and repair of brain tissues. The founders of NeuroFx, together with its management team, have extensive experience in stem cell research and development and/or the necessary backgrounds in product commercialization to bring this therapeutic asset to market. NeuroFx will pursue development of additional indications for its products by partnering with pharmaceutical, regenerative medicine or medical device companies.  The funding NeuroFx is seeking is to support its IND application and complete a Phase 1 trial.

As a second prize winner, NeuroFx will receive two complimentary RESI tickets.

Alejandro Zamorano, Director of Business Development, LSN | Wade Lange, CEO, NeuroFx | Karen Momper, Director, Business Development, NeuroFx | Michael Quigley, Director of Research, LSN

Third Prize Winner: TeVido BioDevices

te

TeVido BioDevices uses innovative 3D bio-printing of a woman’s own living cells – to develop custom grafts for breast cancer reconstruction.  The first product is targeted to improve nipple reconstruction, where current procedures often flatten and fade over time.  TeVido has a platform technology that addresses a significant unmet need in the broad field of reconstructive and aesthetic surgery, a market estimated to be $6B globally.

As a third prize winner, TeVido will receive one complimentary RESI ticket.

te1
Alejandro Zamorano, Director of Business Development, LSN | Laura Bosworth, CEO & co-founder, TeVido BioDevices | Scott Collins, CTO & VP of Research and Development, TeVido BioDevices | Michael Quigley, Director of Research, LSN

LSN Summer Reading Series Issue #3

By Scott Parks, Director of Marketing, LSN 

Scott 2With the third installment of the summer reading series we take a look at the important decision of whether or not one should use a fundraising partner to help them in securing capital. Chapter 3 of The Life Science Executive’s Fundraising Manifesto “Going It Alone or Choosing a Fundraising Partner,” tackles this question head-on, describing what companies would be a suitable fit for fundraising partners, providing a breakdown of the different types in the marketplace today, and advising readers on how to go about vetting a potential partner.

Click here to download/print the PDF.

We hope you enjoy this chapter. Next week, join us for “Chapter 4: Categories of Life Science Investors.”

Enjoyed the preview? Buy now from Amazon.com or Barnes & Noble

Bookcover-Front